세계의 임상 검사 시장 : 규모, 점유율 및 동향분석(유형별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Clinical Laboratory Tests Market Size, Share & Trends Analysis Report By Type (Complete Blood Count, HGB/HCT Tests), By End-use (Primary Clinics, Central Laboratories), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 임상 검사 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 임상 검사 시장 규모는 2030년까지 2,130억 4,000만 달러에 달하고, 2025년부터 2030년까지 CAGR 8.88%를 보일 것으로 추정됩니다. 임상 검사 시장의 성장은 대상 질환의 유병률 증가로 인한 것입니다.

세계 노인 인구는 증가하고 있으며 심혈관 질환과 신장 기능 장애와 같은 질병 개발의 가장 큰 위험 요소로 여겨지고 있습니다. 또한 2050년에는 80세 이상 인구는 15억명 이상으로 두배로 증가하고, 80세 이상의 인구는 3배인 4,260억명에 달할 것으로 예측되고 있습니다.

CVD와 당뇨병과 같은 대상 질환의 유병률 증가는 예측 기간 동안 시장을 밀어 올릴 것으로 예측됩니다. WHO에 따르면 2021년 심혈관 질환은 지난 30년간 세계의 사망률 및 이환율의 주요 원인이며, 177억명이 심혈관 질환에 의해 매년 사망하고 있으며, 이것은 세계의 모든 사망자의 31%에 해당합니다.

또한 임상 검사 개발 및 제제화에 종사하는 주요 기업은 신규 결핵치료제를 개발하고 시장개척에 있어서 경쟁력을 유지하기 위해 공동연구와 파트너십에 주력하고 있습니다. 예를 들어, 2023년 1월, BD는 미생물 검사실의 시료 처리를 자동화하는 3세대 총 실험실 자동화 시스템을 출시했습니다. 2023년 1월, NovoPath LLC는 종양 실험실을 위한 LIS 솔루션을 확장했습니다.

임상 검사 시장 보고서 하이라이트

• 유형별로는 HbA1c 검사 분야가 2024년에 12.39%의 최대 시장 점유율을 차지했으며, 주로 당뇨병과 콜레스테롤 관련 질환의 세계 유병률 상승이 견인했습니다.
• HGB 및 HCT 검사 분야는 예측 기간 중에 가장 빠른 CAGR로 성장할 것으로 예측되고 있습니다.
• 최종 용도별로는 중앙 검사실 부문이 2024년에 시장에서 최대의 점유율을 차지했습니다.
• 1차 클리닉의 최종 용도 분야는 예측 기간 중에 가장 빠른 CAGR을 기록할 전망입니다.
• 북미의 임상 검사 산업은 2024년 시장에서 가장 큰 점유율을 차지하며 앞으로도 지배적인 지위를 유지할 것으로 예측됩니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 임상 검사 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 동향과 전망
• 시장 역학
  • 만성질환의 유병률 상승
  • 기술의 진보
  • 고령화 인구 증가
• 시장 성장 억제요인 분석
  • 규제상의 과제와 모호함
• 업계 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
• 시장 기회 분석
• 시장의 신흥 전략

제4장 임상 검사 시장 : 유형별 추정 및 동향 분석

• 임상 검사 시장 : 유형별 변동 분석
• 유형별
• 전혈구 수
• HGB 및 HCT 검사
• 파운데이션 대사 패널
• BUN 크레아티닌 검사
• 전해질 검사
• HbA1c 검사
• 종합적인 대사 패널 검사
• 간 패널 검사
  • 간염
  • 담관 폐색
  • 간경변
  • 간암
  • 뼈 질환
  • 자가면역질환
  • 기타
• 신장 패널 검사
• 기타
• 미생물학 시장, 2018-2030년
• 병원체 검사

제5장 임상 검사 시장 : 최종 용도별 추정 및 동향 분석

• 임상 검사 시장 : 최종 용도별 변동 분석
• 최종 용도별
• 1차 클리닉
  • 전혈구 수
  • HGB 및 HCT 검사
  • 파운데이션 대사 패널
  • BUN 크레아티닌 검사
  • 전해질 검사
  • HbA1c 검사
  • 종합적인 대사 패널 검사
  • 간 패널 검사
  • 신장 패널 검사
  • 지질 패널 검사
  • 기타
• 중앙 검사실
  • 전혈구 수
  • HGB 및 HCT 검사
  • 파운데이션 대사 패널
  • BUN 크레아티닌 검사
  • 전해질 검사
  • HbA1c 검사
  • 종합적인 대사 패널 검사
  • 간 패널 검사
  • 신장 패널 검사
  • 지질 패널 검사
  • 기타

제6장 임상 검사 시장 : 지역별 추정 및 동향 분석

• 임상 검사 시장 점유율 : 지역별(2024년 및 2030년)
• 시장 점유율 분석 : 지역별(2024년 및 2030년)
• 시장 대시보드 : 지역별
• 세계 시장 현황 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 북미의 임상 검사 시장(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 임상 검사 시장(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 임상 검사 시장(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카의 임상 검사 시장(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 임상 검사 시장(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업 분류
• 전략 매핑
• 기업의 시장 점유율 분석(2024년)
• 기업 프로파일
  • Quest Diagnostics Incorporated.
  • Abbott
  • Cinven
  • Laboratory Corporation of America Holdings
  • ARUP Laboratories
  • OPKO Health, Inc.
  • UNILABS
  • Clinical Reference Laboratory, Inc.
  • Synnovis Group LLP
  • Sonic Healthcare Limited.

JHS

영문 목차

영문목차

Clinical Laboratory Tests Market Growth & Trends:

The global clinical laboratory tests market size is estimated to reach USD 213.04 billion by 2030, registering a CAGR of 8.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the clinical laboratory tests market is attributable to the rising prevalence of target diseases. The use of clinical laboratory tests is on a rise owing to the use of tests in a wide variety of diagnostic purposes that primarily focus on patient health leading to evaluating and formulating proper diagnosis and treatment.

The global geriatric population is increasing and is considered as being the greatest risk factor for the development of conditions, such as cardiovascular diseases and kidney dysfunction. According to WHO, the population aged above 60 years is expected to be 1 in every 6 people by 2030, which accounts for an increase from 1 billion in 2020 to 1.4 billion by 2030. In addition, the number of people aged 80 and above is projected to double to over 1.5 billion by 2050, and people aged above 80 years are expected to triple and reach 426 Billion. Thus, the growing geriatric population is expected to be a high-impact rendering driver for this market over the forecast period.

The growing prevalence of target diseases, such as CVD and diabetes, is anticipated to boost the market over the forecast period. CVD is fatal and leading cause of death worldwide. Presence of high unmet medical needs pertaining to cardiovascular diseases and the subsequent rise in patient awareness are among factors expected to boost the demand for point-of-care lipid testing. According to WHO, in 2021, cardiovascular diseases have been leading cause of mortality and morbidity worldwide in the last three decades, 17.7 Billion people die every year due to cardiovascular diseases, which is 31% of all the deaths worldwide.

Furthermore, key players involved in developing and formulating clinical laboratory tests are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. In addition, increasing adoption of laboratory automation systems is expected to boost the market over the forecast period. For instance, in January 2023[, BD launched a third-generation total laboratory automation system, which automates lab specimen processing for microbiology laboratories. Moreover, in January 2023, NovoPath LLC expanded its LIS solutions for oncology laboratories.

Clinical Laboratory Tests Market Report Highlights:

• Based on type, the HbA1c testing segment held the largest market share at 12.39% in 2024, driven primarily by the rising global prevalence of diabetes and cholesterol-related conditions.
• The HGB/HCT testing type segment is projected to grow at the fastest CAGR during the forecast period.
• By end-use, the central laboratories segment held the largest share of the market in 2024, primarily due to high test volumes and widespread market penetration.
• The primary clinics end-use segment is expected to register the fastest CAGR during the forecast period.
• North America clinical laboratory tests industry held the largest share of market in 2024 and is expected to maintain its dominant position.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Laboratory Tests Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Rising Prevalence of Chronic Diseases
  • 3.4.2. Technological Advancements
  • 3.4.3. Growing Geriatric Population
• 3.5. Market Restraint Analysis
  • 3.5.1. Regulatory Challenges and Ambiguity
• 3.6. Industry Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
• 3.7. Market Opportunity Analysis
• 3.8. Market Emerging Statergies

Chapter 4. Clinical Laboratory Tests Market: Type Estimates & Trend Analysis

• 4.1. Clinical Laboratory Tests Market: Type Movement Analysis
• 4.2. Clinical Laboratory Tests Market Estimates and Forecast, by Type
• 4.3. Complete Blood Count
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. HGB/HCT tests
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Basic metabolic panel
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. BUN creatinine tests
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Electrolytes testing
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. HbA1c tests
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Comprehensive metabolic panel tests
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Liver panel tests
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.2. Hepatitis
    • 4.10.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.3. Bile duct obstruction
    • 4.10.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.4. Liver Cirrhosis
    • 4.10.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.5. Liver Cancer
    • 4.10.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.6. Bone disease
    • 4.10.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.7. Autoimmune disorders
    • 4.10.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.8. Others
    • 4.10.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Renal panel tests
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Others
  • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.13. Microbiology Market, 2018 - 2030 (USD Million)
  • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.14. Pathogen Testing
  • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Clinical Laboratory Tests Market: End Use Estimates & Trend Analysis

• 5.1. Clinical Laboratory Tests Market: End Use Movement Analysis
• 5.2. Clinical Laboratory Tests Market Estimates and Forecast, by End Use
• 5.3. Primary Clinics
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Complete blood count
    • 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. HGB/HCT tests
    • 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.4. Basic metabolic panel
    • 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.5. BUN creatinine tests
    • 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.6. Electrolytes testing
    • 5.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.7. HbA1c tests
    • 5.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.8. Comprehensive metabolic panel tests
    • 5.3.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.9. Liver panel tests
    • 5.3.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.10. Renal panel tests
    • 5.3.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.11. Lipid panel tests
    • 5.3.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.12. Others
    • 5.3.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Central Laboratories
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Complete blood count
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. HGB/HCT tests
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Basic metabolic panel
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. BUN creatinine tests
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Electrolytes testing
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. HbA1c tests
    • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Comprehensive metabolic panel tests
    • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.9. Liver panel tests
    • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.10. Renal panel tests
    • 5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.11. Lipid panel tests
    • 5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.12. Others
    • 5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Clinical Laboratory Tests Market: Regional Estimates & Trend Analysis

• 6.1. Clinical Laboratory Tests Market Share By Region, 2024 & 2030
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Regional Market Dashboard
• 6.4. Global Regional Market Snapshot
• 6.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.6. North America
  • 6.6.1. North America Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.6.2. U.S.
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. U.S. Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.6.3. Canada
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Canada Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.6.4. Mexico
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Mexico Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
• 6.7. Europe
  • 6.7.1. Europe Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.2. UK
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. UK Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.3. Germany
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Germany Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.4. France
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. France Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.5. Italy
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Italy Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.6. Spain
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Spain Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.7. Denmark
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Denmark Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.8. Sweden
    • 6.7.8.1. Key Country Dynamics
    • 6.7.8.2. Competitive Scenario
    • 6.7.8.3. Regulatory Framework
    • 6.7.8.4. Sweden Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.7.9. Norway
    • 6.7.9.1. Key Country Dynamics
    • 6.7.9.2. Competitive Scenario
    • 6.7.9.3. Regulatory Framework
    • 6.7.9.4. Norway Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
• 6.8. Asia Pacific
  • 6.8.1. Asia Pacific Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.8.2. Japan
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Japan Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.8.3. China
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. China Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.8.4. India
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. India Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.8.5. Australia
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Australia Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.8.6. Thailand
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Competitive Scenario
    • 6.8.6.3. Regulatory Framework
    • 6.8.6.4. Thailand Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.8.7. South Korea
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Competitive Scenario
    • 6.8.7.3. Regulatory Framework
    • 6.8.7.4. South Korea Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
• 6.9. Latin America
  • 6.9.1. Latin America Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.9.2. Brazil
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Brazil Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.9.3. Argentina
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Argentina Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
• 6.10. MEA
  • 6.10.1. MEA Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.10.2. South Africa
    • 6.10.2.1. Key Country Dynamics
    • 6.10.2.2. Competitive Scenario
    • 6.10.2.3. Regulatory Framework
    • 6.10.2.4. South Africa Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.10.3. Saudi Arabia
    • 6.10.3.1. Key Country Dynamics
    • 6.10.3.2. Competitive Scenario
    • 6.10.3.3. Regulatory Framework
    • 6.10.3.4. Saudi Arabia Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.10.4. UAE
    • 6.10.4.1. Key Country Dynamics
    • 6.10.4.2. Competitive Scenario
    • 6.10.4.3. Regulatory Framework
    • 6.10.4.4. UAE Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)
  • 6.10.5. Kuwait
    • 6.10.5.1. Key Country Dynamics
    • 6.10.5.2. Competitive Scenario
    • 6.10.5.3. Regulatory Framework
    • 6.10.5.4. Kuwait Clinical Laboratory Tests Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Strategy Mapping
• 7.4. Company Market Share Analysis, 2024
• 7.5. Company Profiles
  • 7.5.1. Quest Diagnostics Incorporated.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Abbott
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Cinven
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Laboratory Corporation of America Holdings
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. ARUP Laboratories
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. OPKO Health, Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. UNILABS
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Clinical Reference Laboratory, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Synnovis Group LLP
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Sonic Healthcare Limited.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료